A patient with BRCA2-mutant high-grade serous ovarian cancer initially responds to platinum and a PARP inhibitor but later progresses. Tumour

Question

A patient with BRCA2-mutant high-grade serous ovarian cancer initially responds to platinum and a PARP inhibitor but later progresses. Tumour sequencing identifies a secondary BRCA2 mutation that restores the open reading frame. What is the most likely biological consequence?

Accepted Answer

Restored homologous recombination with platinum and PARP-inhibitor resistance

Answer

Suppressed drug efflux with renewed PARP-inhibitor sensitivity

Answer

Increased mismatch-repair deficiency with immunotherapy sensitivity

Answer

Loss of nucleotide-excision repair with cisplatin hypersensitivity

Answer

Constitutive HER2 signalling with trastuzumab sensitivity

Diffuse Astrocytoma — SCE Medical Oncology MCQ

A patient with BRCA2-mutant high-grade serous ovarian cancer initially responds to platinum and a PARP inhibitor but later progresses. Tumour sequencing identifies a secondary BRCA2 mutation that restores the open reading frame. What is the most likely biological consequence?